Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer [Yahoo! Finance]
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling [Seeking Alpha]
Candel Therapeutics (CADL) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
Candel Therapeutics (CADL) was downgraded by Zacks Research from "hold" to "strong sell".